Tat-NR2B9c (Tat-NR2Bct; NA-1) is apostsynaptic density-95 (PSD-95)inhibitor, withEC₅₀values of 6.7 nM and 670 nM for PSD-95d2 (PSD-95 PDZ domain 2) and PSD-95d1, respectively. Tat-NR2B9c disrupts the PSD-95/NMDAR interaction, inhibiting NR2A and NR2B binding to PSD-95 withIC₅₀values of 0.5 μM and 8 μM, respectively. Tat-NR2B9c also inhibits neuronal nitric oxide synthase (nNOS)/PSD-95 interaction, and possesses neuroprotective efficacy^[1][2][5].

Tat-NR2B9c is a PSD-95 inhibitor, with an EC₅₀of 6.7 nM for PSD-95d2, representing a >100-fold higher affinity for this domain than for PSD-95d1 (EC₅₀, 0.67 μM). Tat-NR2B9c inhibits NMDAR2A, NMDAR2B, and NMDAR2C binding to PSD-95, with IC₅₀s of 0.5 μM, ~8 μM, and 0.75 μM, respectively.
Tat-NR2B9c also blocks the interaction between PSD-95 and nNOS with an IC₅₀of ~0.2 μM^[1].
Tat-NR2B9c reduces association of PSD-95 with GluN2B by ~50% in the YAC128 striatum, decreases NMDA-induced p38 activation in YAC128 striatal tissue, but shows no effect on the NMDA-induced JNK activation^[2].

Tat-NR2B9c (10 nmol/g, i.v.) reduces infarction volume of male C57BL/6 mice, but has no effect at 3 nM/g^[3].

2518.88

Solid

C₁₀₅H₁₈₈N₄₂O₃₀

500992-11-0

YGRKKRRQRRRKLSSIESDV

Room temperature in continental US; may vary elsewhere.

H₂O : ≥ 50 mg/mL(19.85 mM)

*"≥" means soluble, but saturation unknown.

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。

• 1.

  Tat-NR2B9c is prepared in saline^[4].